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Abstract: The obesity epidemic is a global problem, which is set to increase over time. 
However, the effects of obesity on the respiratory system are often underappreciated. In this 
review, we will discuss the mechanical effects of obesity on lung physiology and the function 
of adipose tissue as an endocrine organ producing systemic inflammation and effecting central 
respiratory control. Obesity plays a key role in the development of obstructive sleep apnea and 
obesity hypoventilation syndrome. Asthma is more common and often harder to treat in the 
obese population, and in this study, we review the effects of obesity on airway inflammation 
and respiratory mechanics. We also discuss the compounding effects of obesity on chronic 
obstructive pulmonary disease (COPD) and the paradoxical interaction of body mass index and 
COPD severity. Many practical challenges exist in caring for obese patients, and we   highlight the 
complications faced by patients undergoing surgical procedures, especially given the increased 
use of bariatric surgery. Ultimately, a greater understanding of the effects of obesity on the 
respiratory disease and the provision of adequate health care resources is vital in order to care 
for this increasingly important patient population.
Keywords: obesity, lung function, obstructive sleep apnea, obesity hypoventilation syndrome, 
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Introduction
Obesity is defined as a body mass index (BMI) greater than 30 kg/m2. Over 1.6 billion 
adults worldwide are overweight, of which 400 million are obese. The World Health 
Organization predicts that 10% of the global population will be obese by 2015.1 The 
prevalence of obesity in European countries has tripled over the past 2 decades, with 
significant health and economic burdens.2 In the United Kingdom, obesity contributes 
to 30,000 deaths a year and £3.5 billion (US $5.4 billion) in health care costs.3 In the 
United States of America, the annual health care costs are 36% greater for an obese 
patient compared with a patient with a normal BMI.4
This increased morbidity and mortality associated with obesity is linked to its 
role in numerous chronic medical conditions, including cardiovascular and metabolic 
diseases, hypercoagulable states, lower back pain, osteoarthritis, and cancer. Obesity 
is also strongly linked with respiratory symptoms and diseases, including exertional 
dyspnea, obstructive sleep apnea syndrome (OSAS), obesity hypoventilation syndrome 
(OHS), chronic obstructive pulmonary disease (COPD), asthma, pulmonary embolism, 
and aspiration pneumonia.5–7
Many obese patients have breathlessness on exertion, and the negative physiologi-
cal effect of obesity on lung function has been demonstrated in numerous studies. International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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However, the influence of obesity in respiratory diseases 
is complex and goes beyond the obvious mechanical and 
physical consequences of weight gain and its associated 
inflammatory and metabolic disorders.
Obesity and respiratory mechanics
Weight gain and rising BMI are associated with decreases in 
lung volumes, which are reflected by a more restrictive venti-
latory pattern on spirometry. Cross-sectional and longitudinal 
studies have demonstrated that a rise in BMI lowers forced 
expiratory volume in 1 second (FEV1), forced vital capacity 
(FVC), functional residual capacity (FRC), and the expiratory 
reserve volume (ERV). In morbid obesity (BMI . 40 kg/m2), 
there is also a modest decrease in residual volume (RV) and 
total lung capacity (TLC). At such extreme levels of obesity, 
FRC approaches RV .4,8–12
Central and peripheral obesity
Two distinct patterns of obesity are recognized in the general 
population: central and peripheral obesity. Central obesity 
is more common in males, with increased adipose tissue in 
the anterior chest wall, anterior abdominal wall, and visceral 
organs. Peripheral obesity is more common in women than 
men, with adiposity located peripherally in the   subcutaneous 
tissue.4
Abdominal obesity is associated with worsening lung 
function and respiratory symptoms.12 Studies that focused 
on waist circumference (WC) found that elevated waist-to-
hip ratio and abdominal height had good correlation with 
impaired lung function.12–14 Various medical conditions are 
also associated with an elevated WC. These include cardio-
vascular diseases (atherosclerosis, ischemic heart disease, 
stroke, hyperlipidemia, and hypertension), type 2 diabetes 
mellitus, and the metabolic syndrome.11,13 Peripheral obesity 
is associated with fewer medical complications and better 
lung function.4
Excess weight on the anterior chest wall due to   obesity 
lowers chest wall compliance and respiratory muscle 
endurance with increase in work of breathing and airway 
resistance.4,11,15 Furthermore, the buildup of adipose tissue 
in the anterior abdominal wall and in the intra-abdominal 
visceral tissue hinders diaphragmatic movement, diminishes 
basal lung expansion during inspiration, and with the closure 
of peripheral lung units, causes ventilation–perfusion abnor-
malities and arterial hypoxemia.12,16 These changes contribute 
to an increase in prevalence of respiratory problems in obese 
individuals, particularly on exertion and in the supine position 
such as during sleep and perioperatively during anesthesia.
Two recent studies have demonstrated that changes in lung 
volume can occur at early stages of obesity and are not limited 
to the morbidly obese individuals (BMI . 40 kg/m2).10,17 
Reduction in FRC and ERV due to loss of basal lung volume 
can occur even in overweight patients (BMI . 25–30 kg/m2) 
or relatively lean individuals with a WC above the normal 
range (.35 in in women; .40 in in men). The site of fat 
accumulation is crucial in determining the effect of obesity 
on respiratory system mechanics. BMI alone does not   provide 
sufficient information about the bodily distribution of fat 
mass (FM).12,13
Pulmonary function and the 
metabolic effects of obesity
The relation between FEV1 and BMI is not a straightforward 
one; FEV1 drops at a much lower rate than FVC or ERV . 
The association between an increase in BMI and   reduction 
in FVC is stronger than with FEV1. Obesity is more often 
associated with a restrictive lung ventilatory defect than an 
  obstructive one, with a low FVC and an elevated FEV1/FVC 
ratio (.70).9,12,13
Low FEV1 values have also been observed in other 
chronic medical diseases, such as hypertension, dyslipidemia, 
cerebrovascular diseases, and lung cancer. This association 
with chronic medical conditions is not clear. However, it 
appears that FEV1 is a good predictor of all-cause morbidity 
and mortality, with increased C-reactive protein (CRP) values 
correlating with reductions in FEV1.4,13,18,19
Abdominal obesity and poor lung function are associated 
with a low-grade inflammatory state, which might contrib-
ute to metabolic disease and ill-health. Elevated levels of 
interleukins (ILs) 6 and 8, tumor necrosis factor α (TNF-α), 
CRP, leptin, and lower levels of adiponectin, which helps in 
regulating insulin sensitivity, have all been observed. Adipose 
tissue is now regarded as an endocrine organ, with release 
of adipocytokines affecting systemic inflammation possibly 
triggered by hypoxemia induced by obesity and related respi-
ratory disorders like OSA, OHS, or COPD.13,18
In a study by Leone et al13 impaired lung function 
(FEV1, FVC, FEV1/FVC) was associated with the com-
ponents of the metabolic syndrome: most strongly with 
abdominal obesity (higher WC) and with elevated low-
density lipoproteins, hypertension, and insulin resistance. 
These correlations were independent of age, sex, BMI, 
history of cardiovascular diseases, smoking, or alcohol use. 
All reduced spirometric measures were associated with a 
restrictive lung pattern, typically seen in obesity-related 
lung changes.13International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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Obesity and respiratory symptoms
Overweight and obese individuals are more likely to have 
respiratory symptoms than individuals with a normal 
BMI, even in the absence of demonstrable lung disease. 
  Studies have shown an increase in self-reported dyspnea 
and wheezing at rest and on exertion in obese compared 
with lean individuals.14,15,20 In a large epidemiological sur-
vey of   Swedish obese patients awaiting bariatric surgery, 
80% reported dyspnea on exertion of two flights of stairs.14 
Recently, Babb et al15 reported a heightened sensation of 
breathlessness on exertion in 37% of 30 otherwise healthy 
obese women.
Kress et al21 calculated respiratory muscle oxygen con-
sumption during ventilation (Vo2 in L/min) in a group of 
intubated and anesthetized morbidly obese patients compared 
with lean controls. Obese subjects exhibited a 16% increase in 
respiratory work and oxygen demand.21 In a study of healthy 
obese women (BMI . 30 kg/m2), Babb et al15 also linked 
exertional dyspnea with an elevated work of breathing. They 
observed a 70% increase in oxygen demand in dyspneic 
obese women when compared with obese controls with 
significantly less exertional breathlessness. Interestingly, 
there was no other identifiable difference in pulmonary func-
tion,   respiratory system mechanics, body composition, or fat 
distribution in the study. Furthermore, the authors found no 
evidence to support cardiac   deconditioning in these patients; 
all the subjects had a normal measured peak Vo2 (L/min).15 
The above studies suggest that the sensation of increased 
dyspnea in obesity is related to an increased oxygen demand 
during ventilation, which is aggravated further by exertion.
Respiratory muscle function has been shown to deteriorate 
in obesity, in a pattern similar to that seen in chronic respira-
tory disease like COPD. This may also be related to a reduc-
tion in the overall fat free mass (FFM – ie, muscle mass).18,22 
This deficiency may contribute to the additional oxygen 
demand required for ventilation and may heighten sensation 
of breathlessness in obese patients. In addition, studies have 
demonstrated that weight loss helps restore the function of 
respiratory muscle. Therefore, the elevated mechanical work 
load of obesity can overburden respiratory muscles through 
a combination of increased work of breathing and apparent 
reduction in respiratory muscle efficiency.14,22
Finally, El-Gamal et al20 investigated the increased 
respiratory drive commonly found in normocapnic obese 
individuals and its association with increasing breathlessness 
and lower lung volumes. Both respiratory symptoms and 
functions improved following bariatric surgery. This further 
emphasizes the fact that weight loss can reverse the   reduction 
in pulmonary function and increased dyspnea   commonly 
associated with obesity.20
It is still unclear why only a proportion of obese individu-
als experience shortness of breath on exertion. Frequently, 
coexisting medical conditions exist that can act as confound-
ing factors when attempting to assess the specific contribution 
obesity plays in the development of respiratory symptoms. 
Some of the most common include smoking, COPD, and 
cardiovascular diseases.14
Obesity and OSA
OSA is characterized by repeated obstructive apneas due to 
a collapsible upper airway (UA) while asleep. This results 
in repetitive nocturnal oxygen desaturations, fragmented 
sleep, and excessive daytime somnolence.23–25 The condi-
tion is treated by application of continuous positive airways 
pressure (CPAP) via a face or nasal mask while the subject 
is asleep. With an “obesity epidemic” currently underway, 
the incidence and prevalence of OSA have now reached new 
heights and is predicted to rise even further.25
Pathophysiology of OSA
The risk of developing OSA increases considerably at a higher 
BMI. If morbidly obese (BMI . 40 kg/m2), the risk of an 
individual of developing OSA lies between 55% and 90%.26 
Other contributing factors include a large neck   circumference 
(.17 in) and a higher oral mallampati score (denoting an 
anatomically narrow UA). Neck circumference is a better pre-
dictor of OSA than BMI. Even more interestingly,   abdominal 
circumference has proven to be a better predictor of OSA than 
both neck circumference and BMI.27–29
In OSA, the UA collapses at a critical closing pressure 
(Pcrit). It is believed that disturbances in the neuromuscular 
control of the pharyngeal dilatory muscles fail to protect the 
UA against increasing extra-luminal pressures.30 The cran-
iofacial variations can predispose toward an anatomically 
unfavorable UA. Obesity seems to play a large part in increas-
ing the passive mechanical pressures, which contribute to 
UA obstruction by increasing fat deposition around the soft 
tissues of the neck and tongue, contributing to an increase 
in extra-luminal pressures in the pharynx that elevates Pcrit, 
thereby increasing the chances of airway collapse.23 Elevated 
levels of obesity have also been shown to worsen nocturnal 
hypoxemia in OSA, in part due to an increase in oxygen 
demand. During apnea, obese patients desaturate at a faster 
level than lean controls.31
Obesity-related reductions in lung volumes (ie, FRC and 
TLC) also increase passive closing pressures at the pharynx.32 International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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Heinzer et al33 demonstrated that a 1.3 L increase in FRC 
during sleep decreased the apnea/hypopnea index (AHI) 
from 62.3 events per hour to 31.2 events per hour. In an ear-
lier study by the same authors, higher CPAP pressures were 
found to be required in order to overcome UA obstruction at 
reduced lung volumes.34 It appears that lower lung volumes 
decrease the caudal traction on the UA during lung inflation, 
producing lesser longitudinal tension on the pharyngeal 
walls, especially in the supine position.35
Obesity is known to account for approximately 30%–50% 
of the variability in AHI.24,25 Numerous longitudinal   studies 
have demonstrated that increasing weight aggravates the 
AHI, which defines the severity of OSA. There is still some 
debate as to whether this association is gender-related. 
An increase in body weight was observed to have a greater 
effect on sleep apnea in men and postmenopausal women 
compared with premenopausal women; however, the data 
were not consistent among the studies.36,37 It was also noticed 
that the rate of increase in apneas is exponential, with steeper 
elevations in AHI at higher levels of BMI. Thus, an advice 
to avoid gaining further weight seems as important as to 
that of losing body weight.36 Regrettably, the converse does 
not seem to apply. For the same reductions in body weight, 
AHI decreases at a much lower rate.36,37 Weight loss can be 
difficult to achieve and even harder to maintain. A viscous 
cycle often develops in patients with OSA, where lack of 
good quality sleep results in lower energy levels during the 
daytime, with a subsequent decline in physical activity. This 
reduction in exercise promotes further weight gain. In addi-
tion, the increasing body weight worsens fatigability and 
exacerbates the OSA.
There are evidence to suggest that poor sleep exacerbates 
weight gain by a direct effect on food intake. In a study on 
healthy subjects who had their sleep time restricted to less than 
4 hours per night for two nights, an increased intake of carbo-
hydrates and calories-dense foods was reported. In addition, 
they were observed to have lower serum leptin and elevated 
ghrelin levels, where leptin is known to act as an appetite sup-
pressant, whereas ghrelin seems to stimulate hunger.25
A number of studies have focused on diet-induced weight 
loss, achieving promising results in patients who underwent 
intensive weight management programs with moderate reduc-
tions in overall weight and AHI. Of note, Toumilehto et al38 
achieved a 63% remission rate in 72 adults with mild OSA 
subjected to very low calorie feeds. However, motivation is 
of paramount importance in order to attain significant results, 
and a few studies exist on the long-term sustained benefit 
of such programs.
Lettieri et al26 studied the improvement in AHI in 
24-  selected OSA patients with morbid obesity who 
underwent bariatric surgery. At 1 year follow-up, despite a 
mean BMI reduction of 18.4 kg/m2 and an average drop in 
AHI of 23.4 events per hour, only one patient experienced 
complete   resolution of OSA. The remaining patients required 
continual use of CPAP, albeit at lower pressure. In the study, 
OSA severity reduced by 50%. However, two patients were 
found to have an increase in their AHI despite significant 
weight loss.26 A meta-analysis by Greenburg et al39 represent-
ing 342 patients in the year 2009, showed similar results with 
bariatric surgery significantly reducing AHI, however, to a 
mean value still consistent with moderately severe OSA.39
Moderate OSA (AHI . 15 events per hour) and severe 
OSA (AHI . 30 events per hour) are associated with an 
increased mortality. Reducing disease severity to an AHI 
of ,15 events per hour (ie, mild OSA) through weight 
loss can help in achieving improved outcomes in OSA 
patients.40 A continual effort to lose weight could also help 
in preventing the emergence of associated medical   conditions 
like insulin resistance, diabetes, and cardiovascular diseases.
Obesity hypoventilation syndrome
Obesity plays a key role in the pathogenesis of OHS. A BMI 
of more than 30 kg/m2 (ie, clinical obesity) together with 
daytime hypercapnia (Paco 2 . 6 kPa) is required for the 
diagnosis of OHS.
Patients with OHS share many physical similarities with 
patients with OSA, including obesity, higher mallampati 
scores, and elevated neck circumference and WC. Many OHS 
patients suffer from sleep-disordered breathing (SDB) and 
commonly present with a history of snoring and witnessed 
apneas. The exact prevalence of OHS in the general popula-
tion is still unknown although epidemiological studies seem 
to suggest that this might be around 10% of OSA patients. 
The largest study (n = 1,141) examining the prevalence of 
hypercapnia in OSA patients discovered an elevated daytime 
hypercapnia in 11% of patients. On evaluating the relation-
ship between the increased Paco 2 and severity of obesity, they 
found the prevalence to be higher with rising BMI.41
However, CO2 retention in OHS seems to be subject to 
a multitude of factors other than an elevated BMI. Indeed, 
many obese patients who develop OSA do not progress to 
OHS and hypercapnia. In addition, a small proportion of 
OHS patients never develop SDB and OSA but remain as 
“pure” OHS patients exhibiting chronic hypoventilation and 
daytime hypercapnea.42 It is believed that normocapnic obese 
subjects manage to overcome the mechanical constraints of International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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obesity-related restrictive lung disease by augmenting their 
respiratory drive and minute ventilation to maintain a normal 
Pao2 and Paco 2. However, in OHS patients, this respiratory 
compensation is lost by disturbances in their central control 
of respiration.42
Many studies have focused on the effects of central 
adipose tissue, whose metabolic and endocrine functions 
have been speculated to influence the central control of 
breathing.20,42,43 Of note, leptin is an adipose-derived   hormone 
that helps in preventing excessive food intake by   suppressing 
appetite, thereby helping to prevent additional weight gain. 
It has been proposed that leptin may also play a role in 
maintaining an adequate minute ventilation in obese sub-
jects. Leptin-deficient obese mice were observed to have a 
reduced ventilatory drive in response to hypercapnia, which 
subsequently improved on administration of leptin.43
A significant proportion of obese patients have elevated 
leptin levels, suggesting a build up of tolerance toward its 
effects (ie, leptin resistance). Makinodan et al44 demonstrated 
a significant association between hypercapnic ventilatory 
response and higher serum leptin levels in obese patients 
with or without OSA. Furthermore, in OSA with chronic 
hypercapnia, the leptin levels were even higher.44 Finally, 
Chin et al45 demonstrated a noticeable reduction in leptin 
levels following CPAP treatment.45 All these studies propose 
an important role of leptin and highlight the potential sig-
nificance of the development of leptin resistance in obesity 
and OHS.
It is important to distinguish among OSA, OHS, and 
OSA/OHS overlap as treatments can be different. These 
conditions could be termed as obesity-related respiratory 
failure. Noninvasive ventilation is used to treat patients with 
hypercapnic respiratory failure due to OHS and patients who 
fail to have adequate ventilation with CPAP. In some centers, 
OHS is among the most frequent indications for domiciliary 
ventilation.46 However, this practice is supported mainly by 
retrospective and case-control analyses, which have shown 
improvement in physiological and health-related quality of 
life parameters. More prospective, randomized, and con-
trolled trials are needed to evidence the management of this 
growing group of patients.
OHS patients often have higher BMIs, more severe 
daytime hypercapnia, and more elevated AHI levels than 
OSA patients. Nocturnal oxygen desaturation events are 
often more profound and frequent, resulting in deeper 
levels of nocturnal hypoxemia and hypercapnia. This can 
predispose to a higher sympathetic activation, elevated 
oxidative stress, and higher cardiovascular risk factors. 
This is compounded by related disorders of the metabolic 
syndrome (ie,   hypercholesterolemia, insulin resistance, and 
diabetes). Chronic daytime hypoxemia and hypercapnia in 
OHS patients is associated with a high risk of developing 
pulmonary hypertension, right-sided heart failure, and cor 
pulmonale. Not surprisingly, the mortality and morbidity 
from OHS have been found to be much higher than from 
both OSA and obesity alone.42
Obesity and asthma
Cross-sectional and longitudinal studies have linked obesity 
with asthma. The frequency of self-reported symptoms of 
breathlessness and wheezing increases with BMI in patients 
with asthma. Furthermore, asthma seems to be commoner in 
the overweight and obese population. In a meta-analysis of 
epidemiological studies, Beuther and Sutherland47 demon-
strated that the prevalence of asthma was higher by 38% in 
overweight patients and by 92% in obese patients. They found 
no differences in the incidence between genders.47 Another 
study by Aaron SD et al49 looked at the possible   over-  diagnosis 
of asthma in obese patients; however, despite a higher rate 
of misdiagnosis of asthma in all patients (up to one-third), 
there was no clear association with obesity.
Studies have not ascertained whether increased respira-
tory symptoms are attributable to asthma or being over-
weight. Schachter et al48 demonstrated that the symptoms of 
asthma increased with a rise in BMI; however, this was not 
associated with an increase in airway hyper-responsiveness 
(AHR).49 McLachlan et al50 found that although inhaled nitric 
oxide was increased in patients with asthma, there was no 
association with either BMI or percentage body fat. Similarly, 
obese patients who manage weight loss by diet or bariatric 
surgery are found to have improvements in their lung func-
tion and asthma symptoms. However, there are no changes 
in AHR or inhaled nitric oxide.51,52 BMI does not seem to 
affect eosinophil counts or serum IgE levels either.53
Without demonstrable correlation between obesity and 
airway inflammation, it has been, therefore, speculated that 
the epidemiological association between obesity and asthma 
is primarily due to ventilatory mechanics rather than an 
inflammatory one.54 King et al55 observed a   significant 
decrease in airway caliber with increasing weight but 
observed no change in AHR or asthma rates. Weight gain 
causes volume loss and a decrease in lung compliance with 
reduction in airway size and tone. These changes can increase 
airflow resistance and obstruction, with reduction in airway 
conductivity.4,10 Reduced airway caliber may predispose 
toward airway trapping and dynamic hyperinflation leading International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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to increasing dyspnea and wheezing, particularly during 
respiratory tract infection.
It has also been suggested that systemic inflammation 
associated with obesity may contribute to glucocorticoid 
insensitivity observed in a few subjects with asthma. Obese 
subjects have elevated inflammatory mediators, namely IL-6, 
IL-8, and TNF-α, which potentially could affect glucocor-
ticoid sensitivity.56 Elevated leptin levels in obesity have 
also been implicated; administered leptin in mice promoted 
AHR and increased IgE levels.57 Finally, Peters-Golden et al58 
demonstrated that the clinical response to beclomethasone 
declined with increasing BMI.
Obese patients with asthma are known to suffer from 
more acute attacks, increased use of asthma medication, 
frequent visits to the emergency department (ED), and more 
hospital admissions than nonobese patients with asthma. 
In a prospective cohort study, Rodrigo and Plaza54 looked 
at adult patients who presented to the ED for the treatment 
of acute asthma. They observed that overweight and obese 
patients had a longer duration of asthmatic symptoms and a 
higher rate of use of inhaled corticosteroids and theophylline 
than normal body weight patients with asthma. Interestingly, 
despite more severe dyspnea and wheezing, in patients with 
asthma with a BMI . 25 kg/m2, they had a higher initial 
FEV1 and peak expiratory flow than nonobese patients 
with asthma. However, obese patients with asthma required 
a longer stay at the ED for treatment, a lower discharge rate 
from the ED, and a higher hospitalization rate than nonobese 
patients with asthma.54
Although there is a paucity of evidence linking obesity, 
AHR, and airway inflammation, the overlap in the respiratory 
symptoms of asthma and obesity patients cannot be ignored. 
Clinicians need to be cautious when diagnosing asthma in 
these patients. Appropriate investigations are often neces-
sary to establish the diagnosis and to help rule other possible 
coexisting medical conditions contributing to the symptoms 
of dyspnea and wheezing.
Obesity and COPD
COPD is characterized by the progressive and largely irre-
versible airflow obstruction and occurs predominately in 
smokers.59 COPD and obesity share a complex interplay of 
similarities, which seems to compound each condition. Both 
are associated with deterioration in lung function, hypoxia, 
and a low-grade systemic inflammation, which predispose 
to increasing medical morbidity and mortality.
The combined effects of obesity and COPD add to dete-
rioration of lung function. FEV1 declines as both   conditions 
worsen.4,11 COPD worsens airflow obstruction and hypoxia 
and, in addition to smoking, increases   pulmonary and 
systemic oxidative stress. This is particularly true in the 
overlap syndrome where the combination of COPD,   obesity, 
and OSA worsens nocturnal and daytime hypoxemia and 
hypercapnia, with over activation of the sympathetic system 
leading to increased cardiovascular and metabolic morbidity 
and mortality with evidence of increased local and systemic 
inflammation.60 Furthermore, in patients with OSA and 
COPD (overlap syndrome), there is a heightened risk of 
developing respiratory failure, pulmonary hypertension, and 
cor pulmonale compared with patients with only COPD. This 
is independent of the degree of airflow obstruction.56
Studies have demonstrated that in early COPD (GOLD 
stages 1 and 2), obesity correlates positively with a rise in 
mortality. This association is strongest with elevated FM and 
increased WC rather than BMI or FFM. It is purported that as 
a consequence of increasing exertional dyspnea secondary to 
COPD, there is a reduction in physical exercise. The use of 
oral steroid medication also increases; patients put on more 
weight and FM and undergo skeletal muscle deconditioning 
with loss of FFM.18
There is a higher prevalence of overweight and obesity 
in the early COPD population compared with the general 
population, but a paradoxically lower BMI in moderate to 
severe COPD patients (GOLD stages 3 and 4).61,62 At these 
later stages of COPD, lower values for BMI (,25 kg/m2) 
seems to adversely affect prognosis. The strongest correlation 
seems to occur with deterioration in FFM, often associated 
with an overall decline in BMI and decrease in FM. In COPD 
and obesity, low-grade inflammation and arterial hypoxemia 
have been associated with a reduction in skeletal muscle tis-
sue, a decrease in muscle fat oxidative capacity, a shift from 
muscle fiber type 1 (slow twitch) to type 2 (fast twitch), and 
a loss of respiratory muscle performance.18
Physiological and metabolic factors related to COPD and 
obesity seems to jeopardize morbidity and mortality further 
when in association. It is clear that these interactions are 
complex and additional studies are required in order to further 
improve our understanding on both conditions.
Obesity and anesthesia
With an ever-increasing demand for surgical procedures involv-
ing anesthesia coupled with a mounting global over-weight 
population, it is little wonder that obesity has become such 
a common and important factor in routine anesthetic assess-
ment. Obesity and its related disorders present an anesthetist 
with numerous difficulties necessitating the need for careful International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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planning and awareness of the common   associated   pitfalls. 
In particular, OSA and OHS should always be considered in 
the obese patient undergoing assessment for surgery.27
Obesity can contribute to complications at all stages 
of anesthesia. It makes intubation and ventilation   difficult 
because of an increase in neck size and small UAs. Ana-
tomical landmarks are often less straightforward, with 
frequent difficulties in establishing vascular access and 
catheterization. Increasing weight makes ambulation difficult 
and appropriate positioning burdensome for radiographic 
imaging. Drug pharmacokinetics is often complex due to a 
disproportionate amount of adipose tissue. Obese surgical 
patients face higher anesthetic risks and often require a longer 
hospital stay with higher health care costs. They are prone 
to more postoperative cardiac and pulmonary complications 
including pneumonia (associated with a 30%–46% mortality 
rate) and thromboembolic disease.13,63
Intubation and airway management
Obese patients often have a thicker neck, smaller UA caliber, 
and poor neck mobility. Mallampati score, used to predict 
difficulties in intubation by gauging tongue size within the 
limited oral cavity, is often high in obese patients and, par-
ticularly, in obese OSA patients. Langeron et al64 identified 
patients  .55 years of age, BMI . 26 kg/m2, snoring, beard, 
and lack of teeth as independent risk factors for difficult 
mask ventilation. Similarly, Kheterpal et al65 listed limited 
mandibular protrusion, a thick neck, sleep apnea, snoring, and 
BMI . 30 kg/m2 as predictors of a complicated intubation.65
OSA and OHS patients often have uncoordinated UA 
dilatory muscle activity, which causes additional problems 
in maintaining an airway.30 This is exacerbated further with 
sedative and anesthetic drugs required during procedures, 
whose dosage can be difficult to determine due to increased 
volume of distribution. Smaller lung volumes have also been 
shown to increase the chances of UA collapsibility.32,33
All this is compounded by the fact that the anesthetist 
needs to successfully intubate within a smaller time window 
as obese patients tend to desaturate faster.16,31 Lower FRC and 
ERV means that obese patients function at reduced oxygen 
reserves. An increased work in breathing places additional 
strain on already impaired cardiac and pulmonary   functions. 
Coexisting medical diseases related to obesity further com-
plicate   anesthesia. Particularly, OSA and OHS patients have 
higher risks for systemic and pulmonary hypertensive diseases, 
coronary artery diseases, cardiac arrhythmias, congestive 
  cardiac failure, and diabetes. Gastroesophageal reflux disease 
can predispose to regurgitation and aspiration pneumonia.16
Ventilation and atelectasis
In the anesthetized patient, mechanical ventillation mimics 
normal breathing but does not reproduce its physiological 
effects.   Mechanically ventilated patients develop pulmonary 
atelectasis, which leads to hypoxemia by increased ventila-
tion–perfusion mismatch and venous shunting. Atelectatic 
lung decreases the FRC;   collapsed lung contains 4 times 
more lung tissue by   volume than aerated lung. This is more 
problematic in the obese patient, as lower lung volumes 
and diminished airway   calibers predispose to compression 
atelectasis. In the supine position, this is most commonly 
seen in the posterior-  dependent regions of the lung, close to 
the diaphragm. Mechanical ventilation distorts normal dia-
phragmatic movement, which is aggravated by the increased 
abdominal pressure present with central adiposity.63 Lung 
atelectasis has been shown to resolve within 24 hours in 
nonobese patients following laparoscopy and within 2 days 
after major surgery. With morbid obesity, lung atelectasis 
persists for much   longer, increasing the risk of the postop-
erative patient to recurrent hypoxemia and postoperative 
pulmonary complications.66
Extubation and postoperative 
recovery
Obesity also poses serious threats during extubation and in 
the immediate postoperative period during the transfer and 
observation of the patient in the recovery room. Ambulation 
of the patient can make continuous monitoring of vital sta-
tistics difficult to achieve. OSA and OHS patients inherently 
have a smaller UA, uncoordinated pharyngeal muscle activ-
ity, and a blunted chemoreceptive control of their ventilation. 
All these factors are made worse by the residual effects of 
administered anesthetic drugs and postextubation pharyngeal 
edema. Therefore, extubation can leave a postoperative 
patient with recurrent UA obstruction and hypoxemia.
Regional anesthesia like spinal or epidural anesthesia 
may offer advantages in the obese surgical patient although 
not without its own technical difficulties. An unsuccess-
ful block is 1.6 times more likely in the obese patient.29 
Conscious sedation is also useful, avoiding deep sedation 
by careful titration.27 If, however, general anesthetic is 
required, rapid sequence induction is often advocated. 
Application of a higher positive end–expiratory pressure 
(PEEP) than usual (PEEP 10 cm of water) in the morbidly 
obese patient is effective for the prevention of atelectasis 
during induction and when atelectasis occurs intraopera-
tively.63 Awake intubation should be considered if serious 
difficulties are anticipated.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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During anesthetic recovery, high-flow oxygen administered 
in the sitting or lateral position is fundamental for the obese 
patient. Continuous or bilevel positive airway pressure (CPAP 
or BiPAP) administered via face mask can help in prevent-
ing UA obstruction and basal lung atelectasis immediately 
following extubation. This is especially true in OSA or OHS 
patients.67 Joris et al67 examined the effect of nasal BiPAP in 
obese patients given for the first 24 hours after undergoing 
gastroplasty. BiPAP with an inspiratory and expiratory posi-
tive airway pressure of 12 and 4 cm H2O, respectively (12/4), 
significantly reduced the fall in FEV1, FVC, and oxygen 
saturation from preoperative baseline, when compared with 
a lower BiPAP pressure of 8/4 cm H2O or only supplemental 
face mask oxygen. Pulmonary function also recovered more 
rapidly in the higher pressure BiPAP group.47
Strategies may be applied before, during, and after 
anesthesia of the obese patient to reduce perioperative 
  complications. Untreated OSA patients should be introduced 
to CPAP therapy before elective surgery and patients are often 
encouraged to bring their own machine with them for the 
operation. Following extubation, these patients struggle less 
against an administered CPAP mask. In   addition,   studies have 
shown that commencing CPAP therapy at least a week before 
surgery helps improve UA   collapsibility, reduce leptin levels, 
and augment respiratory drive and   chemoresponsiveness.27
Conclusion
Obesity presents with various respiratory problems and is 
associated with many medical comorbidities. Despite the 
evidence demonstrating additional health risks and reduced 
quality of life, the rate of obesity is still increasing globally. 
Although genetic susceptibility does play a part, much can 
be done in treatment and prevention of obesity to reduce 
and minimize many medical and respiratory complications. 
Governments need to continue working together with pub-
lic health to encourage a lifestyle with improved diet and 
increased physical activity.
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